|
Index of reports
> Disability (17)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Prohance (Gadoteridol) disability. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Prohance side effects in male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-11
Patient: male, weighing 70.0 kg (154.0 pounds)
Reactions: Nephrogenic Systemic Fibrosis
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Prohance
Indication: Renal Mass
Start date: 2003-07-03
End date: 2003-07-03
Omniscan
Indication: Liver Disorder
Start date: 2004-07-13
End date: 2004-07-13
Omniscan
Indication: Neck Pain
Start date: 2004-07-13
End date: 2004-07-13
Omniscan
Indication: Nuclear Magnetic Resonance Imaging Abdominal
Start date: 2004-07-13
End date: 2004-07-13
Prohance
Indication: Renal Scan
Start date: 2003-07-03
End date: 2003-07-03
Omniscan
Indication: Osteomyelitis
Start date: 2004-07-13
End date: 2004-07-13
Contrast Media
Indication: Decubitus Ulcer
Start date: 2005-04-14
End date: 2005-04-14
Magnevist
Prohance
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2005-04-14
End date: 2005-04-14
Contrast Media
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2005-04-14
End date: 2005-04-14
Omniscan
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2004-07-13
End date: 2004-07-13
Multihance
Indication: Diagnostic Procedure
Optimark
Omniscan
Indication: Nuclear Magnetic Resonance Imaging Brain
Start date: 2004-10-15
End date: 2004-10-15
Other drugs received by patient: Plavix; Iron; Clonidine; Calcitriol; Proamatine; Epogen; Renvela; Cozaar; Calcium Carbonate; Metoprolol Tartrate; Sensipar; Rena-Vite; Phoslo; Hectorol; Renagel; Amlodipine; Fosrenol; Lisinopril; Foltx
Possible Prohance side effects in male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-06
Patient: male, weighing 70.0 kg (154.0 pounds)
Reactions: Pruritus, Hyperkeratosis, Pain, Skin Burning Sensation, Skin Hyperpigmentation, Erythema, Joint Stiffness, Skin Discolouration, Joint Range of Motion Decreased, Skin Lesion, Fibrosis, Extremity Contracture, General Physical Health Deterioration, Muscular Weakness, Nephrogenic Systemic Fibrosis, DRY Skin, Hypoaesthesia, Skin Induration, Deformity, Skin Tightness, Paraesthesia, Skin Plaque, Rash Macular, Gait Disturbance, Scar, Mobility Decreased
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Gadolinium IN Unspecified Drug
Dosage: unk
Start date: 2005-04-14
End date: 2005-04-14
Omniscan
Dosage: 15 ml, unk
Indication: Nuclear Magnetic Resonance Imaging Brain
Start date: 2004-10-15
End date: 2004-10-15
Prohance
Dosage: 17 ml, once
Indication: Nuclear Magnetic Resonance Imaging Abdominal
Start date: 2003-07-03
End date: 2003-07-03
Magnevist
Omniscan
Dosage: 30 ml, once
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2004-07-13
End date: 2004-07-13
Prohance
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2005-04-14
End date: 2005-04-14
Omniscan
Indication: Nuclear Magnetic Resonance Imaging Abdominal
Optimark
Multihance
Other drugs received by patient: Calcitriol; Plavix; Fosrenol; Sensipar; Clonidine; Renvela; Rena-Vite; Calcium Carbonate; Metoprolol Tartrate; Renagel; Cozaar; Phoslo; Epogen; Hectorol; Iron; Amlodipine; Lisinopril; Proamatine; Foltx
Possible Prohance side effects in 78 year old male
Reported by a consumer/non-health professional from Japan on 2012-06-01
Patient: 78 year old male, weighing 56.0 kg (123.2 pounds)
Reactions: Joint Range of Motion Decreased, Skin Discolouration, Nephrogenic Systemic Fibrosis, Gait Disturbance, Skin Induration, Blood Creatinine Increased
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Magnevist
Dosage: 10 ml, once
Indication: Metastases To Lymph Nodes
Start date: 2008-07-29
End date: 2008-07-29
Prohance
Dosage: 26 ml, once
Indication: Nuclear Magnetic Resonance Imaging Brain
Start date: 2008-07-17
End date: 2008-07-17
Other drugs received by patient: Selbex; Omeprazole; SG Granules; Loxonin; Digoxin; Neurotropin [organ Lysate, Standardized]; Metformin Hydrochloride; Olopatadine HCL; Omeprazole; Unasyn; Antebate; Warfarin Sodium; Lendormin; Adalat CC; Lasix; Strong NEO-Minophagen C; Flomox; Celestamine TAB; Atarax; Zefnart
Possible Prohance side effects in 78 year old male
Reported by a consumer/non-health professional from Japan on 2012-05-23
Patient: 78 year old male, weighing 56.0 kg (123.2 pounds)
Reactions: Joint Range of Motion Decreased, Skin Discolouration, Gait Disturbance, Skin Induration, Nephrogenic Systemic Fibrosis
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Magnevist
Dosage: 10 ml, once
Indication: Diagnostic Procedure
Start date: 2008-07-29
End date: 2008-07-29
Prohance
Dosage: 26 ml, once
Indication: Nuclear Magnetic Resonance Imaging Brain
Start date: 2008-07-17
End date: 2008-07-17
Other drugs received by patient: Lasix; Strong NEO-Minophagen C; Lendormin; Omeprazole; Neurotropin [organ Lysate, Standardized]; Antebate; Flomox; Warfarin Sodium; Unasyn; Selbex; Olopatadine HCL; Atarax; Loxonin; Omeprazole; SG Granules; Digoxin; Celestamine TAB; Adalat CC; Zefnart; Metfformin Hydrochloride
Possible Prohance side effects in male
Reported by a physician from Japan on 2012-05-08
Patient: male, weighing 56.0 kg (123.2 pounds)
Reactions: Nephrogenic Systemic Fibrosis
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Prohance
Indication: Nuclear Magnetic Resonance Imaging Brain
Start date: 2008-07-17
End date: 2008-07-17
Meglumine Gadopentetate
Indication: Diagnostic Procedure
Start date: 2008-07-29
End date: 2008-07-29
Meglumine Gadopentetate
Indication: Metastases To Lymph Nodes
Start date: 2008-07-29
End date: 2008-07-29
Other drugs received by patient: Unasyn Oral / 00903601 /; Pyrazolones; Loxonin; Digoxin / 00017701 /; Omeprazole; Omeprazole; Lasix; Lendormin; Atarax; Strong NEO-Minophagen C; Antebate; Adalat CC; Flomox; Celestamine TAB; Lendormin; Atarax; Neurotropin; Warfarin Potassium; Selbex; Olopatadine HCL; Zefnart
Possible Prohance side effects in 43 year old male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-04-30
Patient: 43 year old male, weighing 118.0 kg (259.6 pounds)
Reactions: Pain in Extremity, General Physical Health Deterioration, Skin Induration, Nephrogenic Systemic Fibrosis, Deformity, Skin Tightness, Emotional Distress, Anxiety, Skin Discolouration, Fibrosis, Depression, Mobility Decreased, Scar
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Omniscan
Dosage: 20 ml, once
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2006-04-25
End date: 2006-04-25
Optimark
Indication: Nuclear Magnetic Resonance Imaging
Prohance
Indication: Nuclear Magnetic Resonance Imaging
Multihance
Indication: Nuclear Magnetic Resonance Imaging
Magnevist
Indication: Nuclear Magnetic Resonance Imaging
Omniscan
Dosage: 20 ml, once
Start date: 2006-05-21
End date: 2006-05-21
Other drugs received by patient: Nephrocaps; Losartan Potassium; Aldactone; Insulin; Albumin (Human); Cardizem; Zemplar; Procardia XL; Aranesp; Catapres; Procrit; Phoslo
Possible Prohance side effects in male
Reported by a physician from Japan on 2012-04-24
Patient: male, weighing 56.0 kg (123.2 pounds)
Reactions: Nephrogenic Systemic Fibrosis
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Prohance
Indication: Nuclear Magnetic Resonance Imaging Brain
Start date: 2008-07-17
End date: 2008-07-17
Meglumine Gadopentetate
Indication: Metastases To Lymph Nodes
Start date: 2008-07-29
End date: 2008-07-29
Meglumine Gadopentetate
Indication: Diagnostic Procedure
Start date: 2008-07-29
End date: 2008-07-29
Other drugs received by patient: Flomox; Olopatadine HCL; Atarax; Omeprazole; Lasix; Neurotropin; Zefnart; Lendormin; Atarax; Antebate; Digoxin / 00017701 /; Warfarin Sodium; Celestamine TAB; Pyrazolones; Selbex; Lendormin; Omeprazole; Unasyn Oral / 00903601 /; Loxonin; Adalat CC; Strong NEO-Minophagen C
Possible Prohance side effects in male
Reported by a physician from Japan on 2012-04-19
Patient: male, weighing 56.0 kg (123.2 pounds)
Reactions: Nephrogenic Systemic Fibrosis
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Prohance
Indication: Nuclear Magnetic Resonance Imaging Brain
Start date: 2008-07-17
End date: 2008-07-17
Meglumine Gadopentetate
Indication: Diagnostic Procedure
Start date: 2008-07-29
End date: 2008-07-29
Meglumine Gadopentetate
Indication: Metastases To Lymph Nodes
Start date: 2008-07-29
End date: 2008-07-29
Other drugs received by patient: Loxonin; Digoxin / 00017701 /; Adalat CC; Omeprazole; Zefnart; Lasix; Strong NEO-Minophagen C; Neurotropin; Pyrazolones; Warfarin Sodium; Celestamine TAB; Olopatadine HCL; Atarax; Omeprazole; Unasyn Oral / 00903601 /; Flomox; Lendormin; Antebate; Lendormin; Selbex; Atarax
Possible Prohance side effects in female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-03-05
Patient: female, weighing 78.7 kg (173.1 pounds)
Reactions: Pain, Abasia, Skin Induration, Nephrogenic Systemic Fibrosis, Deformity, Skin Tightness, Emotional Distress, Anxiety, Skin Discolouration, Fibrosis, Coordination Abnormal, Mobility Decreased
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Magnevist
Indication: Imaging Procedure
Gadolinium IN Unspecified Drug
Dosage: unk
Start date: 2008-02-25
End date: 2008-02-25
Gadolinium IN Unspecified Drug
Dosage: unk
Start date: 2004-06-04
End date: 2004-06-04
Gadolinium IN Unspecified Drug
Dosage: unk
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2002-08-24
End date: 2002-08-24
Gadolinium IN Unspecified Drug
Dosage: unk
Start date: 2004-07-16
End date: 2004-07-16
Optimark
Indication: Imaging Procedure
Multihance
Indication: Imaging Procedure
Gadolinium IN Unspecified Drug
Dosage: unk
Start date: 2005-05-25
End date: 2005-05-25
Gadolinium IN Unspecified Drug
Dosage: unk
Start date: 2008-06-04
End date: 2008-06-04
Omniscan
Indication: Imaging Procedure
Prohance
Indication: Imaging Procedure
Gadolinium IN Unspecified Drug
Dosage: unk
Start date: 2004-05-17
End date: 2004-05-17
Other drugs received by patient: Venofer; Aranesp; Clonidine; Metoprolol Succinate; Altace; Coumadin; Atenolol; Renagel; Enalapril Maleate; Epogen; Norvasc; Renvela
Possible Prohance side effects in 72 year old male
Reported by a consumer/non-health professional from United States on 2011-11-21
Patient: 72 year old male, weighing 97.5 kg (214.5 pounds)
Reactions: Restlessness, Urinary Incontinence, Dyskinesia, Toxicity To Various Agents, Tremor, NO Therapeutic Response, DRY Throat, Contrast Media Allergy, Hallucination, Asthenia, Nervousness, Muscle Spasms
Adverse event resulted in: life threatening event, hospitalization, disablity
Drug(s) suspected as cause:
Prohance
Possible Prohance side effects in 42 year old male
Reported by a health professional (non-physician/pharmacist) from United States on 2011-11-15
Patient: 42 year old male, weighing 81.0 kg (178.2 pounds)
Reactions: Skin Exfoliation, Joint Contracture, Pain, Post Inflammatory Pigmentation Change, Neuropathic Arthropathy, Stasis Dermatitis, Anhedonia, Joint Range of Motion Decreased, Skin Ulcer, Oedema, Rash Generalised, General Physical Health Deterioration, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, DRY Skin, Skin Induration, Skin Tightness, Rash Macular, Anxiety, Emotional Distress, Xerosis
Adverse event resulted in: death, disablity
Drug(s) suspected as cause:
Magnevist
Dosage: 20 ml, once
Indication: Nuclear Magnetic Resonance Imaging
Start date: 1999-08-18
End date: 1999-08-18
Magnevist
Omniscan
Omniscan
Dosage: unk
Indication: Nuclear Magnetic Resonance Imaging Brain
Start date: 2005-12-06
End date: 2005-12-06
Optimark
Dosage: 30 ml, once
Start date: 2006-03-23
End date: 2006-03-23
Multihance
Indication: Nuclear Magnetic Resonance Imaging
Optimark
Dosage: 20 ml, once
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2005-09-01
End date: 2005-09-01
Prohance
Indication: Nuclear Magnetic Resonance Imaging
Magnevist
Magnevist
Indication: Nuclear Magnetic Resonance Imaging Brain
Omniscan
Dosage: unk
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2006-05-16
End date: 2006-05-16
Other drugs received by patient: Levothroid; Lotrel; Epogen; Lanoxin; Phoslo; Imuran; Ascorbic Acid W / Folic Acid / Iron / Vitamin B12; Protonix; Acyclovir; Morphine; Reglan; Pravachol; Neurontin; Quinine Sulfate; Imodium; Gastromark; Avinza; Niferex; Coumadin; Lantus; Novolog; Rena-Vite [vit C,vit H,b5,b12,b9,b3,b6,b2,b1 Hcl]; Aciphex; Nephrocaps; Cyclosporine
Possible Prohance side effects in female
Reported by a health professional (non-physician/pharmacist) from United States on 2011-11-10
Patient: female, weighing 78.7 kg (173.1 pounds)
Reactions: Pain, Abasia, Nephrogenic Systemic Fibrosis, Skin Induration, Deformity, Skin Tightness, Emotional Distress, Anxiety, Skin Discolouration, Coordination Abnormal, Fibrosis, Mobility Decreased
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Gadolinium IN Unspecified Drug
Dosage: unk
Start date: 2005-05-25
End date: 2005-05-25
Optimark
Indication: Imaging Procedure
Gadolinium IN Unspecified Drug
Dosage: unk
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2002-08-24
End date: 2002-08-24
Gadolinium IN Unspecified Drug
Dosage: unk
Start date: 2008-02-25
End date: 2008-02-25
Gadolinium IN Unspecified Drug
Dosage: unk
Start date: 2004-07-16
End date: 2004-07-16
Multihance
Indication: Imaging Procedure
Gadolinium IN Unspecified Drug
Dosage: unk
Start date: 2008-06-04
End date: 2008-06-04
Magnevist
Indication: Imaging Procedure
Prohance
Indication: Imaging Procedure
Omniscan
Indication: Imaging Procedure
Gadolinium IN Unspecified Drug
Dosage: unk
Start date: 2004-05-17
End date: 2004-05-17
Gadolinium IN Unspecified Drug
Dosage: unk
Start date: 2004-06-04
End date: 2004-06-04
Other drugs received by patient: Metoprolol; Renagel; Coumadin; Enalapril Maleate; Clonidine; Altace; Atenolol; Renvela; Epogen; Aranesp; Norvasc; Venofer
Possible Prohance side effects in 73 year old male
Reported by a lawyer from United States on 2011-11-08
Patient: 73 year old male
Reactions: Pain, Joint Contracture, Nephrogenic Systemic Fibrosis, Skin Induration, Skin Tightness, Emotional Distress, Anxiety, Anhedonia, Joint Range of Motion Decreased, Injury, Mobility Decreased
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Multihance
Indication: Angiogram
Prohance
Indication: Angiogram
Gadolinium IN Unspecified Drug
Dosage: unk
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2000-05-26
Multihance
Indication: Nuclear Magnetic Resonance Imaging
Gadolinium IN Unspecified Drug
Dosage: 20cc injected
Start date: 2002-07-15
Gadolinium IN Unspecified Drug
Dosage: 30cc
Start date: 2003-11-20
Optimark
Indication: Nuclear Magnetic Resonance Imaging
Gadolinium IN Unspecified Drug
Dosage: unk
Start date: 2002-07-18
Magnevist
Indication: Nuclear Magnetic Resonance Imaging
Omniscan
Indication: Angiogram
Gadolinium IN Unspecified Drug
Dosage: unk
Indication: Angioplasty
Start date: 2004-06-21
Magnevist
Indication: Angiogram
Prohance
Indication: Nuclear Magnetic Resonance Imaging
Optimark
Indication: Angiogram
Omniscan
Dosage: 20cc
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2002-07-15
End date: 2002-07-15
Gadolinium IN Unspecified Drug
Dosage: unk
Indication: Nuclear Magnetic Resonance Imaging Brain
Start date: 1999-07-10
End date: 1999-07-10
Gadolinium IN Unspecified Drug
Dosage: unk
Indication: Angiogram
Start date: 2001-05-14
Gadolinium IN Unspecified Drug
Dosage: unk
Start date: 2004-11-06
Gadolinium IN Unspecified Drug
Indication: Imaging Procedure
Other drugs received by patient: Procrit; Coumadin; Plavix; Actos; Zocor; Renagel; Glipizide; Ramipril; Procrit; Singulair; Allegra; Sertraline Hydrochloride; Flonase; Vitaplex; Iron [citric Acid,ferrous Sulfate]; Furosemide; Valsartan; Metoprolol
Possible Prohance side effects in 57 year old male
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2011-11-08
Patient: 57 year old male
Reactions: Renal Transplant, Nephrogenic Systemic Fibrosis, Immobile
Adverse event resulted in: hospitalization, disablity
Drug(s) suspected as cause:
Prohance
Dosage: 15 ml, single dose, 15 ml, single, 15 ml, single dose, 15 ml, single dose,
Start date: 2006-07-18
End date: 2006-08-17
Prohance
Dosage: 15 ml, single dose, 15 ml, single, 15 ml, single dose, 15 ml, single dose,
Start date: 2006-09-20
End date: 2006-09-20
Prohance
Dosage: 15 ml, single dose, 15 ml, single, 15 ml, single dose, 15 ml, single dose,
Start date: 2007-01-10
End date: 2007-01-10
Prohance
Dosage: 15 ml, single dose, 15 ml, single, 15 ml, single dose, 15 ml, single dose,
Start date: 2007-05-01
End date: 2007-05-01
Omniscan
Dosage: 15 ml, single dose, intravenous;15 ml, single dose, intravenous; 15 ml, single dose, intravenous
Indication: Central Nervous System Abscess
Start date: 2006-05-13
End date: 2006-05-13
Omniscan
Dosage: 15 ml, single dose, intravenous;15 ml, single dose, intravenous; 15 ml, single dose, intravenous
Indication: Central Nervous System Abscess
Start date: 2006-08-23
End date: 2006-08-23
Omniscan
Dosage: 15 ml, single dose, intravenous;15 ml, single dose, intravenous; 15 ml, single dose, intravenous
Indication: Central Nervous System Abscess
Start date: 2006-08-31
End date: 2006-08-31
Possible Prohance side effects in 73 year old male
Reported by a consumer/non-health professional from United States on 2011-11-08
Patient: 73 year old male
Reactions: Pain, Joint Contracture, Skin Induration, Nephrogenic Systemic Fibrosis, Skin Tightness, Anxiety, Emotional Distress, Anhedonia, Joint Range of Motion Decreased, Injury, Mobility Decreased
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Omniscan
Dosage: 20cc
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2002-07-15
End date: 2002-07-15
Prohance
Indication: Nuclear Magnetic Resonance Imaging
Optimark
Indication: Nuclear Magnetic Resonance Imaging
Optimark
Indication: Angiogram
Gadolinium IN Unspecified Drug
Dosage: 20cc injected
Start date: 2002-07-15
Omniscan
Indication: Angiogram
Gadolinium IN Unspecified Drug
Dosage: unk
Indication: Angiogram
Start date: 2001-05-14
Multihance
Indication: Angiogram
Gadolinium IN Unspecified Drug
Dosage: unk
Indication: Angioplasty
Start date: 2004-06-21
Magnevist
Indication: Nuclear Magnetic Resonance Imaging
Gadolinium IN Unspecified Drug
Indication: Imaging Procedure
Prohance
Indication: Angiogram
Gadolinium IN Unspecified Drug
Dosage: unk
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2000-05-26
Gadolinium IN Unspecified Drug
Dosage: unk
Start date: 2004-11-06
Magnevist
Indication: Angiogram
Multihance
Indication: Nuclear Magnetic Resonance Imaging
Gadolinium IN Unspecified Drug
Dosage: unk
Indication: Nuclear Magnetic Resonance Imaging Brain
Start date: 1999-07-10
End date: 1999-07-10
Gadolinium IN Unspecified Drug
Dosage: unk
Start date: 2002-07-18
Gadolinium IN Unspecified Drug
Dosage: 30cc
Start date: 2003-11-20
Other drugs received by patient: Flonase; Plavix; Metoprolol; Zocor; Coumadin; Singulair; Renagel; Sertraline Hydrochloride; Furosemide; Procrit; Allegra; Procrit; Iron [citric Acid,ferrous Sulfate]; Valsartan; Vitaplex; Actos; Glipizide; Ramipril
Possible Prohance side effects in 52 year old female
Reported by a lawyer from United States on 2011-10-26
Patient: 52 year old female, weighing 149.0 kg (327.8 pounds)
Reactions: Skin Exfoliation, Pain, Abasia, Joint Contracture, Joint Stiffness, Joint Range of Motion Decreased, Skin Ulcer, Musculoskeletal Stiffness, Excoriation, Muscular Weakness, General Physical Health Deterioration, Skin Induration, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, Deformity, Pigmentation Disorder, Scar, Mobility Decreased
Adverse event resulted in: death, disablity
Drug(s) suspected as cause:
Multihance
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2008-03-04
End date: 2008-03-04
Magnevist
Dosage: unk unk, once
Indication: Angiogram
Start date: 2003-09-13
End date: 2003-09-13
Prohance
Indication: Angiogram
Start date: 2007-05-11
End date: 2007-05-11
Prohance
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2007-11-09
End date: 2007-11-09
Other drugs received by patient: Diovan; Iron; Renagel; Sensipar; Fosrenol; Epogen; Procrit; Amitriptyline HCL; Rocaltrol; Phoslo; Lantus; Humalog; Clonidine; Norvasc; Coreg; Altace; Aspirin
Possible Prohance side effects in 43 year old male
Reported by a health professional (non-physician/pharmacist) from United States on 2011-10-10
Patient: 43 year old male, weighing 118.0 kg (259.6 pounds)
Reactions: Pain in Extremity, General Physical Health Deterioration, Skin Induration, Nephrogenic Systemic Fibrosis, Deformity, Skin Tightness, Emotional Distress, Anxiety, Skin Discolouration, Depression, Fibrosis, Mobility Decreased, Scar
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Magnevist
Indication: Nuclear Magnetic Resonance Imaging
Omniscan
Dosage: 20 ml, once
Start date: 2006-05-21
End date: 2006-05-21
Prohance
Indication: Nuclear Magnetic Resonance Imaging
Omniscan
Dosage: 20 ml, once
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2006-04-25
End date: 2006-04-25
Multihance
Indication: Nuclear Magnetic Resonance Imaging
Optimark
Indication: Nuclear Magnetic Resonance Imaging
Other drugs received by patient: Insulin [insulin]; Zemplar; Cardizem; Losartan Potassium; Albumin (Human); Aranesp; Phoslo; Catapres; Nephrocaps; Procardia XL; Procrit; Aldactone
|
